Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.

Timothy Clay, Margarita Majem, Enriqueta Felip, Bernard Doger, Enric Carcereny, Martin Forster, Matthew Krebs, Julio Peguero, Christian Mueller, Frederic Triebel

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Pages (from-to)9046
Number of pages1
JournalJournal of Clinical Oncology
Volume39
DOIs
Publication statusPublished - 20 May 2021

Cite this